Levofloxacin for UTI: Uses, Dosage, and Side Effects

Levofloxacin is a fluoroquinolone antibiotic that works well against most bacteria responsible for urinary tract infections, but rising resistance rates and serious potential side effects have pushed it from a first-line treatment to a reserved option in most clinical guidelines. For uncomplicated UTIs, narrower-spectrum antibiotics are now preferred. Levofloxacin still plays a real role when infections are complicated, involve the kidneys, or are caused by bacteria resistant to safer alternatives.

Why Levofloxacin Reaches the Urinary Tract So Effectively

One reason levofloxacin became a go-to UTI drug in the first place is how much of it ends up in your urine. After a single 500 mg oral dose, roughly 80% of the drug is excreted through the kidneys in its active form.¹ That is an unusually high proportion for an antibiotic. Ciprofloxacin, its close relative and the other widely used fluoroquinolone for UTIs, only manages about 36% urinary recovery of the parent drug at its standard 500 mg dose.² That means levofloxacin floods the urinary tract with active drug, which is exactly where you need high concentrations to clear an infection. This pharmacokinetic advantage also lets it be dosed just once a day rather than twice, which can make a real difference in whether people actually finish their course of treatment.

When It Is Typically Prescribed

Levofloxacin is not the drug your doctor should reach for when you have a straightforward bladder infection. For uncomplicated lower UTIs, guidelines have long favored narrower antibiotics like nitrofurantoin and trimethoprim-sulfamethoxazole because they work well against common bladder pathogens while causing less collateral damage to the body’s normal bacteria and less pressure toward resistance. The situations where levofloxacin earns its place are more serious: complicated UTIs involving structural or functional abnormalities of the urinary tract, acute pyelonephritis (kidney infection), and infections caused by organisms that have already tested resistant to first-line drugs.

Levofloxacin also gets used for chronic bacterial prostatitis, a condition that is notoriously hard to treat because most antibiotics penetrate prostate tissue poorly. In a study of 116 men treated with 500 mg daily for 28 days, the clinical success rate was about 77% at one month after finishing treatment, and among those who initially cleared the infection, about 91% remained free of it at six months.³ Fluoroquinolones are one of the few antibiotic classes that penetrate prostate tissue well enough to reach therapeutic levels, which is why they remain a mainstay for that particular diagnosis even as their use for simpler UTIs has narrowed.

Dosing for Different Types of UTI

Two dosing strategies are used, and they match the severity of the infection. For uncomplicated UTIs (when they are prescribed at all), the dose is typically 250 mg once daily for three days. For complicated UTIs and acute pyelonephritis, two regimens have been studied head to head: the older approach of 500 mg daily for 7 to 14 days, and a shorter, higher-dose approach of 750 mg daily for 5 days.

The shorter, higher-dose course performs just as well. A multicenter trial directly comparing the two found that clinical effectiveness was about 90% in both groups, with no meaningful difference in microbiological cure or recurrence rates.⁴ The 750 mg short-course approach has since become the more common prescription for complicated UTIs and pyelonephritis because a shorter course means less total antibiotic exposure, fewer days of potential side effects, and a lower chance of resistance emerging.

How It Stacks Up Against Ciprofloxacin

Ciprofloxacin is the other fluoroquinolone commonly used for urinary infections, and patients sometimes wonder which is better. The short answer is that they perform nearly identically for UTIs. A pooled analysis of clinical trials found no significant difference in end-of-therapy or post-therapy clinical success rates and microbiological eradication rates between the two drugs.⁵ Individual trials back this up. In one randomized comparison for acute pyelonephritis, about 93% of patients in both treatment groups achieved microbiological eradication when the analysis was limited to patients who completed therapy as designed.⁶ A separate trial for complicated UTIs and pyelonephritis found eradication rates of about 88% for levofloxacin and 87% for ciprofloxacin.⁷

The practical differences between the two come down to convenience and pharmacology. Levofloxacin’s once-daily dosing and shorter treatment course (5 days versus ciprofloxacin’s typical 7 to 10 days) can be meaningful advantages. Levofloxacin also achieves higher bactericidal activity in urine over time, especially against gram-positive organisms, because a larger fraction of the drug reaches the urine intact.⁸ In practice, though, this translates to similar overall outcomes for complicated UTIs.

The Resistance Problem

Resistance is the main reason fluoroquinolones have been pushed down the prescribing hierarchy for UTIs. E. coli causes the vast majority of urinary infections, and its resistance to levofloxacin has climbed steadily over the past two decades. A large analysis of urinary E. coli isolates across the United States found levofloxacin resistance rates of 24% or higher among all isolates, and much higher among strains carrying certain resistance genes.⁹ That means if you prescribe levofloxacin without knowing the susceptibility of the particular bug causing the infection, there is roughly a one-in-four chance it will not work at all.

Certain patients face even worse odds. A study of outpatients with UTIs found that people with neurogenic bladders, kidney stones, or a history of taking ciprofloxacin or levofloxacin in the past year were significantly more likely to harbor resistant strains. Prior ciprofloxacin use nearly quadrupled the odds, and prior levofloxacin use tripled them.¹⁰ This cross-resistance between fluoroquinolones is an important point: using one member of the class selects for resistance to the entire class. The 2025 IDSA guideline update for complicated UTIs now specifically suggests avoiding fluoroquinolones if you have been exposed to one in the past 12 months.¹¹

Resistance rates also vary by geography, hospital versus community setting, and patient age. What makes this tricky for individual patients is that national averages may not reflect what is happening locally. Your doctor’s best move when prescribing levofloxacin empirically (before culture results come back) is to know the local antibiogram, which is the resistance pattern data for common pathogens in your community.

Side Effects That Set Fluoroquinolones Apart

Every antibiotic has side effects, but fluoroquinolones carry a set of risks that most other UTI drugs do not, and these risks are the other major reason their use has been restricted. The common side effects are the garden-variety GI symptoms you would expect: nausea, diarrhea, headache. Those usually resolve on their own. The problems that have drawn FDA black-box warnings are more distinctive.

Tendon damage is the most widely known. It ranges from tendinitis to outright tendon rupture, most commonly affecting the Achilles tendon. Data from multiple study types suggest that levofloxacin and its parent compound ofloxacin carry a higher propensity for tendon damage compared to other fluoroquinolones, and the risk appears to be dose- and duration-dependent.¹² The risk is highest in people over 60, those taking corticosteroids, people with kidney problems, and organ transplant recipients. Tendon problems can appear during treatment or weeks after finishing the course, which sometimes makes it hard for patients to connect the symptom to the drug.

Beyond tendons, fluoroquinolones as a class have been linked to peripheral neuropathy (nerve damage causing tingling, numbness, or pain in the hands and feet), aortic aneurysm and dissection, low blood sugar episodes, and QT prolongation (an electrical change in the heart that can trigger dangerous rhythms).¹³ The peripheral neuropathy, in particular, can be irreversible in some cases. These risks are rare in absolute terms for a short UTI course, but they exist, which is why guidelines reserve fluoroquinolones for situations where the benefit clearly outweighs the risk and safer alternatives are not appropriate.

What to Avoid While Taking It

Levofloxacin has a well-documented interaction with minerals and antacids. Products containing aluminum, magnesium, calcium, iron, or zinc can bind to the drug in your gut and dramatically reduce how much gets absorbed into your bloodstream. The mechanism is essentially chemical: the metal ions form complexes with the antibiotic molecule, and aluminum hydroxide (a common antacid ingredient) physically adsorbs levofloxacin in the small intestine, which blocks its uptake.¹⁴ This is not a theoretical concern; it can lead to treatment failure and potentially promote resistant bacteria.¹⁵

The practical workaround is timing. If you need to take antacids, calcium supplements, iron supplements, or multivitamins with minerals, take them at least two hours before or two hours after your levofloxacin dose. This separation gives the antibiotic time to absorb before the interfering minerals arrive. Dairy products contain calcium too, but the amounts in a typical glass of milk or serving of yogurt are generally not enough to cause a clinically meaningful reduction. The bigger culprits are concentrated supplements and antacid tablets.

Kidney Function and Dose Adjustments

Because levofloxacin is cleared so heavily through the kidneys, reduced kidney function causes the drug to accumulate in the body. Both the total body clearance and the renal clearance of levofloxacin track closely with creatinine clearance, the standard measure of kidney function.¹⁶ For people with significantly impaired kidney function, dosing must be reduced to prevent toxicity. Your doctor will typically check kidney function through blood work before prescribing levofloxacin, and the dose adjustment follows a standard schedule based on your estimated creatinine clearance. This is one of those situations where a dose that is perfectly safe for someone with healthy kidneys could cause harm in someone whose kidneys filter more slowly.

Pregnancy and Levofloxacin

Fluoroquinolones have long been avoided during pregnancy because of animal data showing cartilage damage in developing joints. In practice, the human data on birth defects paints a more complicated picture. A pharmacovigilance analysis using the FDA’s adverse event database found that none of the three major fluoroquinolones studied (ciprofloxacin, levofloxacin, and moxifloxacin) increased the overall risk of major congenital malformations, though each was associated with certain specific and rare defects. Of the three, levofloxacin and moxifloxacin appeared to be safer choices than ciprofloxacin during pregnancy when a fluoroquinolone is absolutely necessary.¹⁷ The key word there is “necessary.” The recommendation remains to use safer antibiotics whenever possible during pregnancy and to reserve fluoroquinolones for situations where no reasonable alternative exists.

Impact on Gut Bacteria

An underappreciated consequence of fluoroquinolone use is what it does to the bacteria living in your gut. Even a short course of levofloxacin dramatically reduces the population of normal Enterobacteriaceae (the large family of gut bacteria that includes E. coli) in the intestine. At the same time, the proportion of quinolone-resistant strains among the survivors shoots up, because susceptible bacteria are wiped out and only the resistant ones remain.¹⁸ This shift can persist for weeks after you stop the drug. It matters because those resistant survivors can later cause infections that are harder to treat, and they can pass resistance genes to other bacteria. This collateral damage to the microbiome is one of the strongest arguments for reserving broad-spectrum antibiotics like levofloxacin for infections that truly need them.

Switching From IV to Oral

One genuinely useful property of levofloxacin for hospital patients is that the oral form absorbs almost as completely as the IV form. Bioavailability of oral levofloxacin is near 100%, which means that patients who start on IV therapy in the hospital can often be switched to oral tablets once they are able to eat and drink, without any loss in drug levels. This switch matters for getting people out of the hospital sooner. A pharmacist-managed program that automatically converted eligible patients from IV to oral levofloxacin found significant cost savings at every level of analysis, reducing per-patient costs substantially.¹⁹ Beyond cost, the switch eliminates the risks associated with IV lines, including bloodstream infections, and lets patients go home earlier to finish treatment in their own beds.

Getting a Culture Before Starting Treatment

Given resistance rates above 20% for levofloxacin among urinary E. coli in the United States, empiric prescribing (prescribing based on symptoms before you know which bug is causing the infection) is a gamble that fails more often than it should. The strongest argument for obtaining a urine culture before or at the time of starting any antibiotic is that it lets you confirm the drug will actually work. For uncomplicated UTIs, many providers still prescribe empirically because the infection usually responds to first-line agents and resolves quickly. But for complicated UTIs and pyelonephritis, where levofloxacin is more likely to be considered, a culture with susceptibility testing is standard practice. Newer point-of-care technologies are working toward giving clinicians rapid susceptibility results at the bedside, which could reduce the window of empiric treatment and avoid unnecessary use of broad-spectrum drugs.²⁰ Until those become routine, the urine culture remains the essential tool for making sure levofloxacin is the right choice before committing to a full course.